Base editing for precision therapeutics.

Base editing has achieved significant clinical progress, with promising applications in treating over half of pathogenic genetic variants, including sickle cell disease and hypercholesterolemia.

• Why it matters: Correcting single-nucleotide variants is crucial for many genetic disorders, but current methods face limitations in precision, efficiency, and safety, hindering widespread therapeutic use.
• What they did: Researchers have advanced base editor technology through improvements in specificity, efficiency, and delivery, enabling preclinical and early clinical applications across multiple diseases.
• The result: These developments pave the way for safer, more effective gene therapies, though challenges like off-target effects and delivery remain, requiring further refinement and validation.